Abstract: The present disclosure provides a skin care formulation, which includes silver nanoparticles (AgNPs) and/or silver microparticles (AgMPs), vitamin E, glycerin, hyaluronic acid or a salt thereof, and water. The skin care formulation may be in a form of a serum. The present formulation may be used for treating a skin condition, such as aging, wrinkle, or pigmentation. The present formulation also may be used for moisturizing, rejuvenating, repairing, or improving aesthetic appearance of a skin of a subject in need thereof.

Abstract: Provided is a liquid skin external composition which allows a poorly water-soluble component to be applied to a skin in a liquid state. An assembly of fiber for use in production of a liquid skin external composition, the assembly of fiber comprising (a) a polymer soluble in water and an alcohol or a ketone in a content of 50 mass % or more and 98 mass % or less with respect to the whole assembly of fiber and (b) a poorly water-soluble component in a content of 2 mass % or more and 40 mass % or less with respect to the whole assembly of fiber.

Abstract: Cosmetic composition comprising anionic surfactants, amphoteric surfactants, cationic polymers and liquid fatty substances chosen from fatty alcohols and fatty esters, and cosmetic treatment process The present invention relates to a cosmetic composition, especially a hair composition, comprising: —one or more anionic surfactants, —one or more amphoteric surfactants, —one or more cationic polymers with a high cationic charge density, —one or more liquid fatty substances chosen from non-oxyalkylenated fatty alcohols and monocarboxylic fatty acid esters, and also mixtures thereof. The invention also relates to a cosmetic process for treating, and more particularly for washing and conditioning, keratin materials, especially the hair, using the present composition.

Abstract: A method of preventing contact allergies includes using at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c?Dc with B being OH?, BO2? or H+, Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c? being a relative number having the same absolute value as c. A device, a part of which includes the amphoteric chelating agent, is also described.

Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both. Provided are pharmaceutical compositions adapted to deliver the compounds the lower gastrointestinal tract and methods of using same as monotherapy in the treatment of inflammatory diseases or disorders of the lower gastrointestinal tract, and in combination therapy with 5-aminosalicylate.

Abstract: The present invention relates to compounds of Formulas I-IV and compositions comprising same, including pharmaceutical compositions. The compounds of Formulas I-IV represent new salt forms of specialized pro-resolving mediators (“SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold as described in Formulas I-IV. Also provided are methods for pharmaceutical and non-pharmaceutical uses of such compounds and compositions describing same.

Abstract: The present invention relates to a powder formulation comprising at least one insect repellent and magnesium hydroxide carbonate, and to a process for the preparation of the formulation and to the use of the formulation for repelling insects.

Abstract: Formulation to treat the scalp and/or hair are provided herein. For example, formulations for reducing inflammation of hair follicles are provided, which, in turn, in some aspects, can help facilitate hair strengthening, smoothness and/or shine.

Abstract: Disclosed herein are dentifrices comprising a zinc amino acid halide, which provide a precipitate of zinc oxide upon use with dilution with water and/or saliva. Methods of making and using the dentifrices are also provided.

Abstract: A treatment compound for hoof disease in an animal has a base material and treatment agent. The base material is wax, resin, paste, polymer, oil, or creme. The treatment agent is zinc, copper, oxytetracycline, or tetracycaline. The treatment compound is applied to a hoof area and has a high viscosity in the range of 100,000 to 2,000,000 centipoises to retain the treatment compound on the hoof in a normal animal environment. The treatment compound can be applied by brush, spray, roller, or dipping. The treatment compound is curable by air or UV light to provide a durable, robust shell. The treatment compound can be applied to an interior surface of a boot which is disposed over the hoof to retain the treatment compound on the hoof in normal animal environments. The boot is color coded to indicate length of time that the boot has been applied.

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: A phonophoretic cannabidiol composition comprises an amount of cannabidiol, an amount of a glucose source, such as honey, an amount of aloe vera, and amounts of one or more of glucosamine, methylsulfonylmethane, and chondroitin. A transdermal delivery system for administration of a phonophoretic cannabidiol composition includes a phonophoretic cannabidiol composition, a laser generator comprising an emitter which generates and directs a laser beam to the treatment area, and an ultrasound generator comprising a transducer which generates and transmits a plurality of ultrasonic waves to the treatment area. A method for transdermal delivery of a phonophoretic cannabidiol composition includes selecting laser pretreatment parameters, directing a laser beam to the treatment area, applying an amount of a phonophoretic cannabidiol composition to a treatment area, selecting ultrasonic treatment parameters, and, transmitting a plurality of ultrasonic waves to the treatment area.

Abstract: Disclosed herein are compositions for topical application that effectively deliver antioxidants across the epidermis, dermis, or a combination thereof into cells and/or the bloodstream while concurrently maintaining chemical activity of the antioxidants. In certain aspects, these formulations include emulsions and balms each having a lipophilic carrier and a lipophilic antioxidant solubilized by the lipophilic carrier. Also disclosed herein are methods for making these compositions for topical application.

Abstract: Disclosed are compositions and methods that can be used to improve the skin's visual appearance. In certain aspects, the compositions disclosed herein can include, for example, a combination of ingredients to exfoliate, reduce or eliminate irritation from exfoliation, renew the skin, increase skin radiance, sooth the skin, or increase skin smoothness. This combination of ingredients can be included in a wide-range of product formulations (e.g., serums, eye creams, toners, gels, masks, peels, etc.).

Abstract: The present invention relates to compounds of Formula IV, compositions comprising same, and their use in therapy wherein A and B are each independently a specialized pro-resolving mediator (“SPM”) molecule selected from an E series resolvin, a D series resolvin, and their aspirin-triggered counterparts, and M, R1, R2, X1and X2 are as defined herein.

Abstract: Disclosed herein are dentifrices comprising a zinc amino acid halide, which provide a precipitate of zinc oxide upon use with dilution with water and/or saliva. Methods of making and using the dentifrices are also provided.

Abstract: A pharmaceutical formulation for treatment of shingles is provided. The formulation includes between 0.2 mg of menthol per 120 mL of the formulation and 1.0 mg of menthol per 120 mL of the formulation, camphor water, lime water, and a local anesthetic. The local anesthetic includes one of between 0.6 mL of phenol per 120 mL of the formulation and 2.0 mL of phenol per 120 mL of the formulation and between 0.25% concentration by weight of lidocaine and 5% concentration by weight of lidocaine.

Abstract: The present invention relates to the use of hydroxymethyl-group-containing glycosaminoglycans, such as in particular hydroxymethyl-hyaluronic acid, for the treatment and prevention of infectious diseases or malignant or premalignant diseases, in particular of the skin or mucosa. The invention additionally provides a preparation method for glycosaminoglycans modified with hydroxymethyl groups.

Abstract: The method of treating diabetic wounds using biosynthesized nanoparticles includes administering an effective amount of silver and gold nanoparticles to a patient in need thereof. The silver and gold nanocomposite is prepared by ‘biosynthesis”, i.e., by providing a first aqueous solution of a noble metal salt or a noble metal oxide; providing a second solution of an aqueous plant extract, and combining the first solution and the second solution to produce a solution including nanoparticles of the noble metal. The second solution includes a plant extract obtained from Solenostemma argel, Trigonella foenum-graecum and Cinnamomum cassia. The metal salt can include silver nitrate (AgNO3) and chloroauric acid (HAuCl4). Nanoparticles of gold and nanoparticles of silver are prepared separately, and then mixed to obtain a composition containing a gold and silver nanocomposite.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.

Abstract: The present invention pertains generally to the field of therapy, and more specifically to the field of therapy for herpes simplex and herpes zoster, and more particularly, to methods of reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis (cold sores on the lips), herpes genitalis (genital herpes), and herpes zoster (shingles, zona), by topical administration of polyethylene glycol (PEG), or a composition comprising PEG.

Abstract: Disclosed herein are dentifrices comprising a zinc amino acid halide, which provide a precipitate of zinc oxide upon use with dilution with water and/or saliva. Methods of making and using the dentifrices are also provided.

Abstract: A composition for the treatment of acne includes hydrolyzed Psoralea Corylifolia, containing a component bakuchiol, is solubilized in a water-based solution. The composition is for topical application to the skin. In a specific implementation, the composition is a water-based acne gel. In a specific implementation, a composition includes Bakutrol™, which includes bakuchiol, and bisabolol. The composition can include a polysorbate surfactant. In implementations, these ingredients are combined with other active ingredients, including for example, salicylic acid. A process of preparation of the composition allows for the stabilization of Bakutrol in solution.

Abstract: The present application relates to dental adhesive and restoration compositions comprising benzalkonium chloride, having the general structure C6H5CH2N(CH3)2—R—Cl, and salts thereof in a range between approximately 0.01% and approximately 10% by weight in dental primer, dental adhesive, dental resin, and other dental polymeric compositions or in dental solutions. In particular, it has been shown that dental compositions comprising benzalkonium chloride result in the inhibition of the hydrolytic activity of MMP on the dentin adhesive layer, thereby reducing the degradation of bond strength between a resulting dental restoration and the underlying dental tissue.

Abstract: An eye cream comprises the following components: 2-16 parts of pearl, 0.2-2 parts of borax, 10-28 parts of VE, 0.005-0.05 parts of muscone, 0.2-3 parts of borneol, 30-90 parts of eye circles 338Y324 and 0.05-2 parts of zinc carbonate hydroxide in weight. The eye cream has good effects of increasing moisture, continuously locking water, inhibiting melanin, increasing the skin brightness and the skin texture.

Abstract: A new additive for plastics (for example, polyethylene) is prepared by reacting a fatty acid ester of glycerol (such as glycerol monostearate) with a source of a reactive divalent metal selected from zinc, calcium, and magnesium. In an embodiment, Zinc oxide is the reactive divalent metal and the reaction is conducted in the presence of an acid such as zinc acetate. In one embodiment, a molar excess of zinc oxide (compared to the fatty acid ester) is used. The additive is suitable for use in the preparation of injection molded parts, rotomolded parts, and films.

Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.

Abstract: Compositions and methods for modifying the composition of tight junction complexes and/or improving epithelial barrier function are disclosed.

Abstract: A water-soluble anti-inflammatory cream is disclosed. The cream is a composition of between about 7.5% and about 30% by weight of a healing oil; between about 1% and about 6% by weight of an herbal extract; between about 0% and about 3.5% by weight of microencapsulated amino acids; and at least 39.4% by weight water.

Abstract: A composition used to facilitate healing of cold sores, fever blisters and canker sore that includes potassium, rubidium, zinc, calcium and sodium is provided. This composition is compounded into a polyethylene glycol ointment containing allantoin (0.5 to 2 percent) and camphor (0.1 to 3 percent) and/or menthol (0.1 to 1 percent). In another embodiment, a method to treat cold sores, fever blisters and canker sores is provided by applying an effective amount of this composition to cold sores, fever blisters and canker sores of a subject in need of treatment thereof.

Abstract: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).

Abstract: Methods of altering properties of tissues, by providing an effective modifying amount of zinc, which may be in the form of zinc ions. This is accomplished through the use of topical compositions containing one or more zinc-containing components such as salts and/or other zinc compounds or complexes, particularly zinc acetate. Altering properties of tissues includes increasing or decreasing fatty tissue, increasing or decreasing epidermal thickness, increasing elastin content, and preventing or treating gum regression or atrophy. Also disclosed is the provision of a contact lens coated with a zinc-containing material, to improve vision by increasing elastin content of the lens of the eye through release of zinc ions.

Abstract: A process for the preparation of nano zinc oxide particles is disclosed. The process comprises of dissolving a zinc metal precursor in a solvent to obtain a first solution and dissolving a base in an alcohol to obtain an alkali solution. The alkali solution is then added to the first solution over a predetermined period of time to obtain nano zinc oxide particles in solution.

Abstract: The present invention relates to a fluid-permeable primary dressing in strip form, having pores, perforations or honeycomb lattices, which enable the passage of fluid, further having a content of at least one heavy metal present in elemental or ionic form.

Abstract: A topical composition is provided. The topical composition comprises from about 0.25 to about 1.5 percent by weight hydrocortisone; from about 0.5 to about 5.0 percent by weight lidocaine; and from about 0.25 to about 3.0 percent by weight clotrimazole.

Abstract: The present invention is directed towards various topical protective formulations which may be used as an adjunct in preventing the spread of a broad range of sexually transmitted diseases. The product is intended to be used as a topical lotion, cream, emulsion, or the like. The film forming excipients and active ingredients in the following formulations have demonstrated unique skin protective barrier properties with enhanced persistence that inhibits transmission of sexually transmitted diseases.

Abstract: The present invention is directed towards various topical protective formulations, which may be used as an adjunct in preventing the spread of a broad range of sexually transmitted diseases. The product is intended to be used as a topical lotion, cream, emulsion, or the like. The film forming excipients and active ingredients in the following formulations have demonstrated unique skin protective barrier properties with enhanced persistence that inhibits transmission of sexually transmitted diseases.

Abstract: Compositions and methods for preventing microbial infections are disclosed.

Abstract: A new skin care system includes day and night skin cream compositions comprising nutrients and antioxidants for use by children between six months and eighteen years of age. The day skin cream composition provides protection from UV radiation and the night skin cream composition contains no sun protection ingredients and elevated levels of nutrients and antioxidants. A child-friendly bottle for each composition can be used by young children without difficulty. A fragrance included in each composition is popular with children, and the bottle for the day composition has graphics indicating day-time use and the bottle for the night composition has graphics indicating night-time use. The day composition is applied topically each day to the face after tooth-brushing, and the night composition is applied topically to the face each night after tooth-brushing.

Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).

Abstract: The present invention provides an aqueous ophthalmic composition containing (A) a terpenoid, (B) zinc chloride, and (C) at least one member selected from the group consisting of cellulose-based polymeric compounds, vinyl-based polymeric compounds, polyethylene glycols and dextran. According to the present invention, an aqueous ophthalmic composition is provided in which adsorption of the terpenoid to a container can be inhibited, thereby making it possible to inhibit the reduction in the terpenoid content for a long period of time, the aqueous ophthalmic composition having some excellent actions such as an inhibitory action for histamine release, and an inhibitory action for discharges from the eyes.

Abstract: Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: In one aspect, a wound treatment system includes an inner layer comprising a foam material impregnated with a zinc oxide containing composition with or without calamine and/or ichthammol and in the presence or absence of antimicrobial agent (inorganic and/or organic). An optional outer layer comprises a short/long stretch compression bandage. In another aspect, a method of manufacturing the foam article impregnated with the zinc oxide containing composition is disclosed. In yet another aspect, a method of applying the wound treatment system to a patient's leg is disclosed. In still another aspect, a kit is provided including a foam layer impregnated with a zinc oxide containing composition; optionally, an elastic bandage component (e.g., long or short stretch elastic bandage); and, optionally, an outer stocking or sleeve, wherein the bandage system components are packaged together.

Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.

Abstract: The present invention provides a non-irritating, sprayable wound dressing composition and a non-irritating, non-sprayable ointment for treating wounds in mammals such as horses or dogs. The composition of the present invention is made of an acceptable carrier and an active ingredient made of organic salts of naturally occurring cations having the capacity to facilitate healing of wounds.

Abstract: This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure. The present invention more specifically discloses a method of rejuvenating skin affected by intrinsic aging and/or photo-induced aging comprising topically applying a topical formulation to the skin, wherein said topical formulation is comprised of ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, carnosic acid, ?-tocopherol, 0.01 weight percent to 20 weight percent of a mixture of ethyl lactate and isoamyl lactate, wherein the weight ratio of the ethyl lactate to the isoamyl lactate is within the range of 1:10 to 20:1, and a pharmaceutically acceptable carrier.

Abstract: The invention relates to formulations for topical use comprising an antiseborrheic agent and an antimicrobial and/or antibacterial agent for the treatment of inflammatory dermatoses. In particular said formulations comprise melatonin and an antimicrobial or antibacterial agent, can be used in the pharmaceutical, cosmetic/cosmeceutical or dermatological field and are particularly suitable for the treatment of acne and of the clinical symptoms associated thereto.

Abstract: A cleansing lotion composition of zinc derivatives, aloe vera, lanolin and a mixture of water-based emulsifying agents for reducing itchiness, promoting healing and reducing inflammation around the anorectal area of a human subject is disclosed. The subject conveniently spreads a suitable amount of the cleansing lotion placed on toilet paper and applies to the affected anorectal area. The excess lotion could be wiped clean with fresh toilet paper after each application.

Abstract: The addition of low concentrations of combinations of water-soluble organic salts of zinc to gels, creams, lotions or ointments can increase the ability of these products to reduce or prevent exogenous irritants from causing irritation of the underlying substrate. The addition of low concentrations of combinations of water-soluble organic zinc salts to these gels, creams, lotions or ointments also can reduce the irritation of skin or mucous membranes caused by the addition of potentially-irritating substances such as spermicides, microbicides, fungicides or other therapeutic agents to the gel, cream, lotion or ointment. The advantages of this anti-irritant approach over others, which generally employ high concentrations of single zinc salts, are the reduced potential for zinc toxicity, the reduced potential for toxicity related to zinc itself, and the preservation of the desirable biological properties of potentially-irritating therapeutic substances added to the gel, cream, lotion or ointment.